Table of Content

1 Report Overview
1.1 Vasculitis Drug Definition
1.2 Market by Type
1.2.1 Global Vasculitis Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Blisibimod
1.2.3 CCX-168
1.2.4 Gevokizumab
1.2.5 Rituximab Biosimilar
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Vasculitis Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Polyarteritis Nodosa
1.3.3 Thrombotic Vasculitis
1.3.4 Granulomatous Vasculitis
1.3.5 Lymphocytic Vasculitis
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Vasculitis Drug Sales
2.1 Global Vasculitis Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Vasculitis Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Vasculitis Drug Revenue by Region
2.3.1 Global Vasculitis Drug Revenue by Region (2018-2023)
2.3.2 Global Vasculitis Drug Revenue by Region (2024-2034)
2.4 Global Vasculitis Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Vasculitis Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Vasculitis Drug Sales Quantity by Region
2.6.1 Global Vasculitis Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Vasculitis Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Vasculitis Drug Sales Quantity by Manufacturers
3.1.1 Global Vasculitis Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Vasculitis Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Vasculitis Drug Sales in 2024
3.2 Global Vasculitis Drug Revenue by Manufacturers
3.2.1 Global Vasculitis Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Vasculitis Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Vasculitis Drug Revenue in 2024
3.3 Global Vasculitis Drug Sales Price by Manufacturers
3.4 Global Key Players of Vasculitis Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Vasculitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Vasculitis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Vasculitis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Vasculitis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Vasculitis Drug Sales Quantity by Type
4.1.1 Global Vasculitis Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Vasculitis Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Vasculitis Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Vasculitis Drug Revenue by Type
4.2.1 Global Vasculitis Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Vasculitis Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Vasculitis Drug Revenue Market Share by Type (2018-2034)
4.3 Global Vasculitis Drug Price by Type
4.3.1 Global Vasculitis Drug Price by Type (2018-2023)
4.3.2 Global Vasculitis Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Vasculitis Drug Sales Quantity by Application
5.1.1 Global Vasculitis Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Vasculitis Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Vasculitis Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Vasculitis Drug Revenue by Application
5.2.1 Global Vasculitis Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Vasculitis Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Vasculitis Drug Revenue Market Share by Application (2018-2034)
5.3 Global Vasculitis Drug Price by Application
5.3.1 Global Vasculitis Drug Price by Application (2018-2023)
5.3.2 Global Vasculitis Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Vasculitis Drug Sales by Company
6.1.1 North America Vasculitis Drug Revenue by Company (2018-2023)
6.1.2 North America Vasculitis Drug Sales Quantity by Company (2018-2023)
6.2 North America Vasculitis Drug Market Size by Type
6.2.1 North America Vasculitis Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Vasculitis Drug Revenue by Type (2018-2034)
6.3 North America Vasculitis Drug Market Size by Application
6.3.1 North America Vasculitis Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Vasculitis Drug Revenue by Application (2018-2034)
6.4 North America Vasculitis Drug Market Size by Country
6.4.1 North America Vasculitis Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Vasculitis Drug Revenue by Country (2018-2034)
6.4.3 North America Vasculitis Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Vasculitis Drug Sales by Company
7.1.1 Europe Vasculitis Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Vasculitis Drug Revenue by Company (2018-2023)
7.2 Europe Vasculitis Drug Market Size by Type
7.2.1 Europe Vasculitis Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Vasculitis Drug Revenue by Type (2018-2034)
7.3 Europe Vasculitis Drug Market Size by Application
7.3.1 Europe Vasculitis Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Vasculitis Drug Revenue by Application (2018-2034)
7.4 Europe Vasculitis Drug Market Size by Country
7.4.1 Europe Vasculitis Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Vasculitis Drug Revenue by Country (2018-2034)
7.4.3 Europe Vasculitis Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Vasculitis Drug Sales by Company
8.1.1 China Vasculitis Drug Sales Quantity by Company (2018-2023)
8.1.2 China Vasculitis Drug Revenue by Company (2018-2023)
8.2 China Vasculitis Drug Market Size by Type
8.2.1 China Vasculitis Drug Sales Quantity by Type (2018-2034)
8.2.2 China Vasculitis Drug Revenue by Type (2018-2034)
8.3 China Vasculitis Drug Market Size by Application
8.3.1 China Vasculitis Drug Sales Quantity by Application (2018-2034)
8.3.2 China Vasculitis Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Vasculitis Drug Sales by Company
9.1.1 APAC Vasculitis Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Vasculitis Drug Revenue by Company (2018-2023)
9.2 APAC Vasculitis Drug Market Size by Type
9.2.1 APAC Vasculitis Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Vasculitis Drug Revenue by Type (2018-2034)
9.3 APAC Vasculitis Drug Market Size by Application
9.3.1 APAC Vasculitis Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Vasculitis Drug Revenue by Application (2018-2034)
9.4 APAC Vasculitis Drug Market Size by Region
9.4.1 APAC Vasculitis Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Vasculitis Drug Revenue by Region (2018-2034)
9.4.3 APAC Vasculitis Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Vasculitis Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Vasculitis Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Vasculitis Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Vasculitis Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Vasculitis Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Vasculitis Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Vasculitis Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Vasculitis Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Vasculitis Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Overview
11.1.3 Merck Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Merck Vasculitis Drug Products and Services
11.1.5 Merck Vasculitis Drug SWOT Analysis
11.1.6 Merck Recent Developments
11.2 Bayer
11.2.1 Bayer Company Information
11.2.2 Bayer Overview
11.2.3 Bayer Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Bayer Vasculitis Drug Products and Services
11.2.5 Bayer Vasculitis Drug SWOT Analysis
11.2.6 Bayer Recent Developments
11.3 Farmalider
11.3.1 Farmalider Company Information
11.3.2 Farmalider Overview
11.3.3 Farmalider Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Farmalider Vasculitis Drug Products and Services
11.3.5 Farmalider Vasculitis Drug SWOT Analysis
11.3.6 Farmalider Recent Developments
11.4 Hainan Pharmaceutical Factory
11.4.1 Hainan Pharmaceutical Factory Company Information
11.4.2 Hainan Pharmaceutical Factory Overview
11.4.3 Hainan Pharmaceutical Factory Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Hainan Pharmaceutical Factory Vasculitis Drug Products and Services
11.4.5 Hainan Pharmaceutical Factory Vasculitis Drug SWOT Analysis
11.4.6 Hainan Pharmaceutical Factory Recent Developments
11.5 Shanghaihuangxiang Lantian Pharmaceutical
11.5.1 Shanghaihuangxiang Lantian Pharmaceutical Company Information
11.5.2 Shanghaihuangxiang Lantian Pharmaceutical Overview
11.5.3 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Products and Services
11.5.5 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug SWOT Analysis
11.5.6 Shanghaihuangxiang Lantian Pharmaceutical Recent Developments
11.6 Huzhou Konch Pharmaceutical
11.6.1 Huzhou Konch Pharmaceutical Company Information
11.6.2 Huzhou Konch Pharmaceutical Overview
11.6.3 Huzhou Konch Pharmaceutical Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Huzhou Konch Pharmaceutical Vasculitis Drug Products and Services
11.6.5 Huzhou Konch Pharmaceutical Vasculitis Drug SWOT Analysis
11.6.6 Huzhou Konch Pharmaceutical Recent Developments
11.7 CSPC Ouyi Pharmaceutical
11.7.1 CSPC Ouyi Pharmaceutical Company Information
11.7.2 CSPC Ouyi Pharmaceutical Overview
11.7.3 CSPC Ouyi Pharmaceutical Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 CSPC Ouyi Pharmaceutical Vasculitis Drug Products and Services
11.7.5 CSPC Ouyi Pharmaceutical Vasculitis Drug SWOT Analysis
11.7.6 CSPC Ouyi Pharmaceutical Recent Developments
11.8 Sino-US Zibo Xinhua-Perrigo Pharmaceutical
11.8.1 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information
11.8.2 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Overview
11.8.3 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Products and Services
11.8.5 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug SWOT Analysis
11.8.6 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments
11.9 Hubei Biocause Pharmaceutical
11.9.1 Hubei Biocause Pharmaceutical Company Information
11.9.2 Hubei Biocause Pharmaceutical Overview
11.9.3 Hubei Biocause Pharmaceutical Vasculitis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Hubei Biocause Pharmaceutical Vasculitis Drug Products and Services
11.9.5 Hubei Biocause Pharmaceutical Vasculitis Drug SWOT Analysis
11.9.6 Hubei Biocause Pharmaceutical Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Vasculitis Drug Value Chain Analysis
12.2 Vasculitis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vasculitis Drug Production Mode & Process
12.4 Vasculitis Drug Sales and Marketing
12.4.1 Vasculitis Drug Sales Channels
12.4.2 Vasculitis Drug Distributors
12.5 Vasculitis Drug Customers
13 Market Dynamics
13.1 Vasculitis Drug Industry Trends
13.2 Vasculitis Drug Market Drivers
13.3 Vasculitis Drug Market Challenges
13.4 Vasculitis Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Vasculitis Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Blisibimod
Table 3. Major Manufacturers of CCX-168
Table 4. Major Manufacturers of Gevokizumab
Table 5. Major Manufacturers of Rituximab Biosimilar
Table 6. Major Manufacturers of Others
Table 7. Global Vasculitis Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Vasculitis Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Vasculitis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Vasculitis Drug Revenue Market Share by Region (2018-2023)
Table 11. Global Vasculitis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Vasculitis Drug Revenue Market Share by Region (2024-2034)
Table 13. Global Vasculitis Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 14. Global Vasculitis Drug Sales by Region (2018-2023) & (K Pcs)
Table 15. Global Vasculitis Drug Sales Market Share by Region (2018-2023)
Table 16. Global Vasculitis Drug Sales by Region (2024-2034) & (K Pcs)
Table 17. Global Vasculitis Drug Sales Market Share by Region (2024-2034)
Table 18. Global Vasculitis Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 19. Global Vasculitis Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 20. Global Vasculitis Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Vasculitis Drug Revenue Share by Manufacturers (2018-2023)
Table 22. Global Vasculitis Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 23. Global Key Players of Vasculitis Drug, Industry Ranking, 2021 VS 2024
Table 24. Global Vasculitis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Vasculitis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vasculitis Drug as of 2024)
Table 26. Global Key Manufacturers of Vasculitis Drug, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Vasculitis Drug, Product Offered and Application
Table 28. Global Key Manufacturers of Vasculitis Drug, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Vasculitis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 31. Global Vasculitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 32. Global Vasculitis Drug Sales Quantity Share by Type (2018-2023)
Table 33. Global Vasculitis Drug Sales Quantity Share by Type (2024-2034)
Table 34. Global Vasculitis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Vasculitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Vasculitis Drug Revenue Share by Type (2018-2023)
Table 37. Global Vasculitis Drug Revenue Share by Type (2024-2034)
Table 38. Vasculitis Drug Price by Type (2018-2023) & (USD/Pcs)
Table 39. Global Vasculitis Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 40. Global Vasculitis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 41. Global Vasculitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 42. Global Vasculitis Drug Sales Quantity Share by Application (2018-2023)
Table 43. Global Vasculitis Drug Sales Quantity Share by Application (2024-2034)
Table 44. Global Vasculitis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Vasculitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Vasculitis Drug Revenue Share by Application (2018-2023)
Table 47. Global Vasculitis Drug Revenue Share by Application (2024-2034)
Table 48. Vasculitis Drug Price by Application (2018-2023) & (USD/Pcs)
Table 49. Global Vasculitis Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 50. North America Vasculitis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 51. North America Vasculitis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 52. North America Vasculitis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 53. North America Vasculitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 54. North America Vasculitis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 55. North America Vasculitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Vasculitis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 57. North America Vasculitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 58. North America Vasculitis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 59. North America Vasculitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Vasculitis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 61. North America Vasculitis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 62. North America Vasculitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Vasculitis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 64. North America Vasculitis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 65. Europe Vasculitis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 66. Europe Vasculitis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 67. Europe Vasculitis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 68. Europe Vasculitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 69. Europe Vasculitis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 70. Europe Vasculitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Vasculitis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 72. Europe Vasculitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 73. Europe Vasculitis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 74. Europe Vasculitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Vasculitis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 76. Europe Vasculitis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 77. Europe Vasculitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Vasculitis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 79. Europe Vasculitis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 80. China Vasculitis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 81. China Vasculitis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 82. China Vasculitis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 83. China Vasculitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 84. China Vasculitis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 85. China Vasculitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Vasculitis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 87. China Vasculitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 88. China Vasculitis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 89. China Vasculitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Vasculitis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 91. APAC Vasculitis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 92. APAC Vasculitis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 93. APAC Vasculitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 94. APAC Vasculitis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 95. APAC Vasculitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Vasculitis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 97. APAC Vasculitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 98. APAC Vasculitis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 99. APAC Vasculitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Vasculitis Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 101. APAC Vasculitis Drug Revenue by Region (2018-2023) & (US$ Million)
Table 102. APAC Vasculitis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Vasculitis Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 104. APAC Vasculitis Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 105. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 106. Middle East, Africa and Latin America Vasculitis Drug Revenue by Company (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 108. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 109. Middle East, Africa and Latin America Vasculitis Drug Revenue by Type (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Vasculitis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 112. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 113. Middle East, Africa and Latin America Vasculitis Drug Revenue by Application (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Vasculitis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Vasculitis Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Vasculitis Drug Revenue by Country (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Vasculitis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 119. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 120. Merck Company Information
Table 121. Merck Description and Overview
Table 122. Merck Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 123. Merck Vasculitis Drug Product and Services
Table 124. Merck Vasculitis Drug SWOT Analysis
Table 125. Merck Recent Developments
Table 126. Bayer Company Information
Table 127. Bayer Description and Overview
Table 128. Bayer Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 129. Bayer Vasculitis Drug Product and Services
Table 130. Bayer Vasculitis Drug SWOT Analysis
Table 131. Bayer Recent Developments
Table 132. Farmalider Company Information
Table 133. Farmalider Description and Overview
Table 134. Farmalider Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 135. Farmalider Vasculitis Drug Product and Services
Table 136. Farmalider Vasculitis Drug SWOT Analysis
Table 137. Farmalider Recent Developments
Table 138. Hainan Pharmaceutical Factory Company Information
Table 139. Hainan Pharmaceutical Factory Description and Overview
Table 140. Hainan Pharmaceutical Factory Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 141. Hainan Pharmaceutical Factory Vasculitis Drug Product and Services
Table 142. Hainan Pharmaceutical Factory Vasculitis Drug SWOT Analysis
Table 143. Hainan Pharmaceutical Factory Recent Developments
Table 144. Shanghaihuangxiang Lantian Pharmaceutical Company Information
Table 145. Shanghaihuangxiang Lantian Pharmaceutical Description and Overview
Table 146. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 147. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product and Services
Table 148. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug SWOT Analysis
Table 149. Shanghaihuangxiang Lantian Pharmaceutical Recent Developments
Table 150. Huzhou Konch Pharmaceutical Company Information
Table 151. Huzhou Konch Pharmaceutical Description and Overview
Table 152. Huzhou Konch Pharmaceutical Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 153. Huzhou Konch Pharmaceutical Vasculitis Drug Product and Services
Table 154. Huzhou Konch Pharmaceutical Vasculitis Drug SWOT Analysis
Table 155. Huzhou Konch Pharmaceutical Recent Developments
Table 156. CSPC Ouyi Pharmaceutical Company Information
Table 157. CSPC Ouyi Pharmaceutical Description and Overview
Table 158. CSPC Ouyi Pharmaceutical Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 159. CSPC Ouyi Pharmaceutical Vasculitis Drug Product and Services
Table 160. CSPC Ouyi Pharmaceutical Vasculitis Drug SWOT Analysis
Table 161. CSPC Ouyi Pharmaceutical Recent Developments
Table 162. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information
Table 163. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Description and Overview
Table 164. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 165. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product and Services
Table 166. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug SWOT Analysis
Table 167. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments
Table 168. Hubei Biocause Pharmaceutical Company Information
Table 169. Hubei Biocause Pharmaceutical Description and Overview
Table 170. Hubei Biocause Pharmaceutical Vasculitis Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 171. Hubei Biocause Pharmaceutical Vasculitis Drug Product and Services
Table 172. Hubei Biocause Pharmaceutical Vasculitis Drug SWOT Analysis
Table 173. Hubei Biocause Pharmaceutical Recent Developments
Table 174. Key Raw Materials Lists
Table 175. Raw Materials Key Suppliers Lists
Table 176. Vasculitis Drug Distributors List
Table 177. Vasculitis Drug Customers List
Table 178. Vasculitis Drug Market Trends
Table 179. Vasculitis Drug Market Drivers
Table 180. Vasculitis Drug Market Challenges
Table 181. Vasculitis Drug Market Restraints
Table 182. Research Programs/Design for This Report
Table 183. Key Data Information from Secondary Sources
Table 184. Key Data Information from Primary Sources
List of Figures
Figure 1. Vasculitis Drug Product Picture
Figure 2. Global Vasculitis Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Vasculitis Drug Market Share by Type in 2024 & 2034
Figure 4. Blisibimod Product Picture
Figure 5. CCX-168 Product Picture
Figure 6. Gevokizumab Product Picture
Figure 7. Rituximab Biosimilar Product Picture
Figure 8. Others Product Picture
Figure 9. Global Vasculitis Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 10. Global Vasculitis Drug Market Share by Application in 2024 & 2034
Figure 11. Polyarteritis Nodosa
Figure 12. Thrombotic Vasculitis
Figure 13. Granulomatous Vasculitis
Figure 14. Lymphocytic Vasculitis
Figure 15. Others
Figure 16. Vasculitis Drug Report Years Considered
Figure 17. Global Vasculitis Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 18. Global Vasculitis Drug Revenue 2018-2034 (US$ Million)
Figure 19. Global Vasculitis Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 20. Global Vasculitis Drug Sales Quantity 2018-2034 (K Pcs)
Figure 21. Global Vasculitis Drug Sales Quantity Market Share by Region (2018-2023)
Figure 22. Global Vasculitis Drug Sales Quantity Market Share by Region (2024-2034)
Figure 23. North America Vasculitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. North America Vasculitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Europe Vasculitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. Europe Vasculitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. China Vasculitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. China Vasculitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. APAC Vasculitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 30. APAC Vasculitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 32. Middle East, Africa and Latin America Vasculitis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 33. The Top 10 and Top 5 Players Market Share by Vasculitis Drug Sales Quantity in 2024
Figure 34. The Top 10 and Top 5 Players Market Share by Vasculitis Drug Revenue in 2024
Figure 35. Vasculitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 36. Global Vasculitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 37. Global Vasculitis Drug Revenue Market Share by Type (2018-2034)
Figure 38. Global Vasculitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 39. Global Vasculitis Drug Revenue Market Share by Application (2018-2034)
Figure 40. North America Vasculitis Drug Revenue Market Share by Company in 2024
Figure 41. North America Vasculitis Drug Sales Quantity Market Share by Company in 2024
Figure 42. North America Vasculitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 43. North America Vasculitis Drug Revenue Market Share by Type (2018-2034)
Figure 44. North America Vasculitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 45. North America Vasculitis Drug Revenue Market Share by Application (2018-2034)
Figure 46. North America Vasculitis Drug Revenue Share by Country (2018-2034)
Figure 47. North America Vasculitis Drug Sales Quantity Share by Country (2018-2034)
Figure 48. U.S. Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Canada Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 50. Europe Vasculitis Drug Sales Quantity Market Share by Company in 2024
Figure 51. Europe Vasculitis Drug Revenue Market Share by Company in 2024
Figure 52. Europe Vasculitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 53. Europe Vasculitis Drug Revenue Market Share by Type (2018-2034)
Figure 54. Europe Vasculitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 55. Europe Vasculitis Drug Revenue Market Share by Application (2018-2034)
Figure 56. Europe Vasculitis Drug Revenue Share by Country (2018-2034)
Figure 57. Europe Vasculitis Drug Sales Quantity Share by Country (2018-2034)
Figure 58. Germany Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 59. France Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 60. U.K. Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Italy Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 62. Russia Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 63. China Vasculitis Drug Sales Quantity Market Share by Company in 2024
Figure 64. China Vasculitis Drug Revenue Market Share by Company in 2024
Figure 65. China Vasculitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 66. China Vasculitis Drug Revenue Market Share by Type (2018-2034)
Figure 67. China Vasculitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 68. China Vasculitis Drug Revenue Market Share by Application (2018-2034)
Figure 69. APAC Vasculitis Drug Sales Quantity Market Share by Company in 2024
Figure 70. APAC Vasculitis Drug Revenue Market Share by Company in 2024
Figure 71. APAC Vasculitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 72. APAC Vasculitis Drug Revenue Market Share by Type (2018-2034)
Figure 73. APAC Vasculitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 74. APAC Vasculitis Drug Revenue Market Share by Application (2018-2034)
Figure 75. APAC Vasculitis Drug Revenue Share by Region (2018-2034)
Figure 76. APAC Vasculitis Drug Sales Quantity Share by Region (2018-2034)
Figure 77. Japan Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 78. South Korea Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 79. China Taiwan Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 81. India Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 82. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Vasculitis Drug Revenue Market Share by Company in 2024
Figure 84. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Vasculitis Drug Revenue Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Vasculitis Drug Revenue Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America Vasculitis Drug Sales Quantity Share by Country (2018-2034)
Figure 89. Middle East, Africa and Latin America Vasculitis Drug Revenue Share by Country (2018-2034)
Figure 90. Brazil Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Mexico Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Turkey Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 93. Israel Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 94. GCC Countries Vasculitis Drug Revenue (2018-2034) & (US$ Million)
Figure 95. Vasculitis Drug Value Chain
Figure 96. Vasculitis Drug Production Process
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Distributors Profiles
Figure 99. Bottom-up and Top-down Approaches for This Report
Figure 100. Data Triangulation
Figure 101. Key Executives Interviewed